Genfit S.A. — Investor Relations & Filings

Genfit S.A. is a late-stage biopharmaceutical company dedicated to discovering and developing therapeutic solutions for severe and life-threatening liver diseases with high unmet medical needs. The company's pipeline focuses on drug candidates with complementary mechanisms of action that target key pathophysiological pathways in conditions such as Acute-on-Chronic Liver Failure (ACLF). A key asset, developed in partnership with Ipsen, received accelerated approval from the U.S. FDA for a chronic liver disease. This therapy works by activating specific receptors to reduce inflammation and manage bile acids. Genfit also develops diagnostic solutions and strategically expands its portfolio through acquisitions and licensing agreements to advance its research in liver disease.